SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.

Autor: Pandey G; Department of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Mazzacurati L; Department of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Rowsell TM; Department of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Horvat NP; Department of Immunology, Moffitt Cancer Center, Tampa, Florida, USA., Amin NE; Department of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Zhang G; Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Akuffo AA; Department of Immunology, Moffitt Cancer Center, Tampa, Florida, USA., Colin-Leitzinger CM; Department of Immunology, Moffitt Cancer Center, Tampa, Florida, USA., Haura EB; Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Kuykendall AT; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA., Zhang L; Department of Pathology, Moffitt Cancer Center, Tampa, Florida, USA., Epling-Burnette PK; Department of Immunology, Moffitt Cancer Center, Tampa, Florida, USA., Reuther GW; Department of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida, USA.; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Jun; Vol. 99 (6), pp. 1040-1055. Date of Electronic Publication: 2024 Mar 05.